Biotechnology · Philadelphia, Pennsylvania, United States
$0.63
+4.55% (+$0.03)2026-07-09
Smart-Money SignalNeutral · 53/100— Insider open-market flow is flat over 90 days
Net Income-$8.7M
EPS$-0.09
Market Cap$57.6M
Price Performance
Historical data including institutional events
Company Profile
M
Martin Lehr
CEO & Executive Director
Context Therapeutics Inc., a biopharmaceutical company, develops products for the treatment of solid tumors.
Its lead program candidate is CTIM-76, an anti-Claudin 6 (CLDN6) x anti-CD3 bispecific antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of a CLDN6 bispecific monoclonal antibody for cancer therapy.
The company was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
